KRAS and lung adenocarcinoma: A different study performed an integrative analysis of genomic, transcriptomic, and proteomic data from early stage and chemo-refractory KRAS-mutant lung adenocarcinoma (LUAC) and discovered three strong KRAS-mutant LUAC subgroups, each of which was dominated by co-occurring genetic events in STK11/LKB1 (the KL subgroup), TP53 (the KP subgroup), and CDKN2A/B inactivation along with low expression of the NKX2-1 (TTF1) transcription factor (the KC subgroup) [204].